GOGOA Mobility Robots

GOGOA operates at the intersection of healthcare robotics and wearable exoskeletons, with applications in clinical rehabilitation and workplace injury prevention. Its offering is broader than a single-device proposition: HANK and BELK+ address gait and lower-limb support, Hand of Hope and BESK target upper-limb rehabilitation, and HELK is designed for lumbar assistance. Movex Clinics adds a service component by combining robotic neurorehabilitation with therapy. The company describes its Assist-As-Needed control approach as adapting assistance to a person’s movement intention, and says HANK has CE marking for sale in Europe. The company is categorized in Health Care and Robotics and has an employee-size band of 11–50. No distinct competitor names are identified in the available company profile; the listed similarity entries repeat GOGOA itself and therefore do not support a reliable named peer comparison. Its competitive position relative to other exoskeleton makers consequently remains uncertain. The evidence supports a specialized European rehabilitation-robotics profile, not a defensible claim of category leadership or market share.

GOGOA’s trajectory reflects a long-running, specialized engineering business rather than a clearly documented rapid-scaling venture. The company was founded in 2015, and its listed CEO and CTO have held their roles since July of that year. The recorded funding history includes a Seed round dated Dec 1, 2016 with no amount specified and a Grant dated Dec 1, 2018 valued at $1,775,784. Separate grant figures in the financial signals—€1.4 million dated October 2015 and €1.2 million with no date—do not reconcile with the two-round count and total funding figure, so they should not be treated as evidence of a consistent cumulative financing trajectory. Hiring information references the REVITAL project and qualified employment, without specifying hiring volume or dates. Overall, the record indicates continued activity across product and service areas, while the timing and scale of growth remain difficult to verify.